Table 2. Incidence of adverse events (%) whilst taking nintedanib in the INPULSIS-1 and INPULSIS-2 trials (16).

Adverse event	INPULSIS-1	INPULSIS-2
Diarrhoea	61.5	63.2
Nausea	22.7	26.1
Cough	15.2	11.6
Reduced appetite	8.4	12.8
Vomiting	12.9	10.3
Weight loss	8.1	11.2